Skip to content
Research Article Open access CC BY 3.0

Evaluation of the Effectiveness of Oseltamivir for the Treatment of 2009 Pandemic Influenza A (H1N1)

Luana Lenzi, Mônica H. C. Grochocki, Lineu R. Silva, Astrid Wiens, Angela M. Mello, Roberto Pontarolo

International Journal of TROPICAL DISEASE & Health · pp. 132–144 · Published 17 May 2012

10.9734/IJTDH/2012/1310

Abstract

Aims: Evaluate retrospectively the effectiveness of treatment with oseltamivir in a Brazilian subpopulation infected during the 2009 pandemic influenza A(H1N1) and compare drug activity based on the presence or absence of other disease risk factors and also the time from onset of symptoms to initiation of treatment. Study Design: Observational and retrospective. Place and Duration of Study: Federal University of Paraná and Parana State Secretary of Health, between April 2009 and December 2010. Methodology: 1,917 patients were included (842 men, 1,075 women; age range 0-90 years) with positive diagnosis for the 2009 influenza virus A (H1N1) characterized by RT-PCR, whose notification forms were available at the time of data collection and that contained information of the use or not of oseltamivir. The patients were categorized by age, gender, symptoms, presence or absence of co morbidities, outcomes (cure or death) and treated or untreated with oseltamivir. The odds ratio (OR) was estimated using a multivariate logistic regression analysis. Kaplan-Meier method was used to determine if differences existed between the survival of untreated patients and oseltamivir treated patients. Results: Out of 1,917 patients, 1,644 had cleared the infection and 273 patients died. Age, education level, cardiopathies, nephropathies, immunodepression, smoking, diabetes, systemic arterial hypertension, obesity, diarrhea, dyspnea, hemoptysis and pneumonia were considered risk factors. The use of oseltamivir provided about 32.3 times more likely to clear the infection compared with untreated patients. Moreover, the effectiveness of oseltamivir is reduced by approximately 7-fold in smoking patients. For each day that passed to initiate treatment after the onset of symptoms, the risk of death increased by 32.3%.  Conclusion: The findings suggest that treatment with oseltamivir was effective in producing favorable patient outcomes in those who contracted the 2009 influenza A (H1N1) strain.

Influenza A virus H1N1 subtype oseltamivir prognosis risk factors treatment effectiveness

References (19)

  1. 1 Factors Associated With Death or Hospitalization Due to Pandemic 2009 Influenza A(H1N1) Infection in California [DOI]
  2. 2 Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza [DOI]
  3. 3 Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study [DOI]
  4. 4 Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection [DOI]
  5. 5 Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza [DOI]
  6. 6 Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women [DOI]
  7. 7 Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome [DOI]
  8. 8 Fatalities Associated with the 2009 H1N1 Influenza A Virus in New York City [DOI]
  9. 9 Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada [DOI]
  10. 10 The first influenza pandemic of the new millennium [DOI]
  11. 11 Mortality of 2009 pandemic influenza A(H1N1) in Germany [DOI]
  12. 12 Antivirals for the treatment and prevention of epidemic and pandemic influenza [DOI]
  13. 13 Ensaios clínicos pragmáticos: uma opção na construção de evidências em saúde [DOI]
  14. 14 Oseltamivir: A First Line Defense Against Swine Flu [DOI]
  15. 15 2009 H1N1: risk factors for hospitalization in a matched case-control study [DOI]
  16. 16 Efficacy and Effectiveness Approaches in Behavioral Treatment Trials [DOI]
  17. 17 Clinical manifestations, therapy and outcome of pandemic influenza a (H1N1) 2009 in hospitalized patients [DOI]
  18. 18 Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice [DOI]
  19. 19 Influenza A (H1N1): manifestaciones clínicas e indicaciones profilácticas y terapéuticas [DOI]

Cited by 3

The characteristics, clinical manifestations and outcomes of pandemic influenza A (H1N1) 2009 in the elderly

Luana Lenzi, Astrid Wiens, Roberto Pontarolo · Revista da Sociedade Brasileira de Medicina Tropical · 2013

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

33

Page views

0

PDF downloads

3

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.